Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice

Namit Sharma, Stephanie Everingham, Li Fan Zeng, Zhong-Yin Zhang, Reuben Kapur, Andrew W B Craig

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Acquired mutations in KIT are driver mutations in systemic mastocytosis (SM). Here, we tested the role of SHP2/PTPN11 phosphatase in oncogenic KIT signaling using an aggressive SM mouse model. Stable knock-down (KD) of SHP2 led to impaired growth, colony formation, and increased rates of apoptosis in P815 cells. This correlated with defects in signaling to ERK/Bim, Btk, Lyn, and Stat5 pathways in P815-KD cells compared to non-targeting (NT). Retro-orbital injections of P815 NT cells in syngeneic DBA/2 mice resulted in rapid development of aggressive SM within 13-16 days characterized by splenomegaly, extramedullary hematopoiesis, and multifocal liver tumors. In contrast, mice injected with P815 SHP2 KD cells showed less disease burden, including normal spleen weight and cellularity, and significant reductions in mastocytoma cells in spleen, bone marrow, peripheral blood and liver compared to NT controls. Treatment of human mast cell leukemia HMC-1 cells or P815 cells with SHP2 inhibitor II-B08, resulted in reduced colony formation and cell viability. Combining II-B08 with multi-kinase inhibitor Dasatinib showed enhanced efficacy than either inhibitor alone in blocking cell growth pathways and cell viability. Taken together, these results identify SHP2 as a key effector of oncogenic KIT and a therapeutic target in aggressive SM.

Original languageEnglish
Pages (from-to)6130-6141
Number of pages12
JournalOncotarget
Volume5
Issue number15
StatePublished - 2014

Fingerprint

Non-Receptor Type 11 Protein Tyrosine Phosphatase
Systemic Mastocytosis
Disease Progression
Cell Survival
Mast-Cell Leukemia
Spleen
Extramedullary Hematopoiesis
Mastocytoma
Inbred DBA Mouse
Mutation
Liver
Splenomegaly
Growth
Phosphotransferases
Bone Marrow
Apoptosis
Weights and Measures

Keywords

  • Aggressive systemic mastocytosis
  • KIT
  • SHP2 inhibitor
  • SHP2/PTPN11

ASJC Scopus subject areas

  • Oncology

Cite this

Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice. / Sharma, Namit; Everingham, Stephanie; Zeng, Li Fan; Zhang, Zhong-Yin; Kapur, Reuben; Craig, Andrew W B.

In: Oncotarget, Vol. 5, No. 15, 2014, p. 6130-6141.

Research output: Contribution to journalArticle

Sharma, Namit ; Everingham, Stephanie ; Zeng, Li Fan ; Zhang, Zhong-Yin ; Kapur, Reuben ; Craig, Andrew W B. / Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice. In: Oncotarget. 2014 ; Vol. 5, No. 15. pp. 6130-6141.
@article{75285e28875041bfbe45ab679f3d86de,
title = "Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice",
abstract = "Acquired mutations in KIT are driver mutations in systemic mastocytosis (SM). Here, we tested the role of SHP2/PTPN11 phosphatase in oncogenic KIT signaling using an aggressive SM mouse model. Stable knock-down (KD) of SHP2 led to impaired growth, colony formation, and increased rates of apoptosis in P815 cells. This correlated with defects in signaling to ERK/Bim, Btk, Lyn, and Stat5 pathways in P815-KD cells compared to non-targeting (NT). Retro-orbital injections of P815 NT cells in syngeneic DBA/2 mice resulted in rapid development of aggressive SM within 13-16 days characterized by splenomegaly, extramedullary hematopoiesis, and multifocal liver tumors. In contrast, mice injected with P815 SHP2 KD cells showed less disease burden, including normal spleen weight and cellularity, and significant reductions in mastocytoma cells in spleen, bone marrow, peripheral blood and liver compared to NT controls. Treatment of human mast cell leukemia HMC-1 cells or P815 cells with SHP2 inhibitor II-B08, resulted in reduced colony formation and cell viability. Combining II-B08 with multi-kinase inhibitor Dasatinib showed enhanced efficacy than either inhibitor alone in blocking cell growth pathways and cell viability. Taken together, these results identify SHP2 as a key effector of oncogenic KIT and a therapeutic target in aggressive SM.",
keywords = "Aggressive systemic mastocytosis, KIT, SHP2 inhibitor, SHP2/PTPN11",
author = "Namit Sharma and Stephanie Everingham and Zeng, {Li Fan} and Zhong-Yin Zhang and Reuben Kapur and Craig, {Andrew W B}",
year = "2014",
language = "English",
volume = "5",
pages = "6130--6141",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "15",

}

TY - JOUR

T1 - Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice

AU - Sharma, Namit

AU - Everingham, Stephanie

AU - Zeng, Li Fan

AU - Zhang, Zhong-Yin

AU - Kapur, Reuben

AU - Craig, Andrew W B

PY - 2014

Y1 - 2014

N2 - Acquired mutations in KIT are driver mutations in systemic mastocytosis (SM). Here, we tested the role of SHP2/PTPN11 phosphatase in oncogenic KIT signaling using an aggressive SM mouse model. Stable knock-down (KD) of SHP2 led to impaired growth, colony formation, and increased rates of apoptosis in P815 cells. This correlated with defects in signaling to ERK/Bim, Btk, Lyn, and Stat5 pathways in P815-KD cells compared to non-targeting (NT). Retro-orbital injections of P815 NT cells in syngeneic DBA/2 mice resulted in rapid development of aggressive SM within 13-16 days characterized by splenomegaly, extramedullary hematopoiesis, and multifocal liver tumors. In contrast, mice injected with P815 SHP2 KD cells showed less disease burden, including normal spleen weight and cellularity, and significant reductions in mastocytoma cells in spleen, bone marrow, peripheral blood and liver compared to NT controls. Treatment of human mast cell leukemia HMC-1 cells or P815 cells with SHP2 inhibitor II-B08, resulted in reduced colony formation and cell viability. Combining II-B08 with multi-kinase inhibitor Dasatinib showed enhanced efficacy than either inhibitor alone in blocking cell growth pathways and cell viability. Taken together, these results identify SHP2 as a key effector of oncogenic KIT and a therapeutic target in aggressive SM.

AB - Acquired mutations in KIT are driver mutations in systemic mastocytosis (SM). Here, we tested the role of SHP2/PTPN11 phosphatase in oncogenic KIT signaling using an aggressive SM mouse model. Stable knock-down (KD) of SHP2 led to impaired growth, colony formation, and increased rates of apoptosis in P815 cells. This correlated with defects in signaling to ERK/Bim, Btk, Lyn, and Stat5 pathways in P815-KD cells compared to non-targeting (NT). Retro-orbital injections of P815 NT cells in syngeneic DBA/2 mice resulted in rapid development of aggressive SM within 13-16 days characterized by splenomegaly, extramedullary hematopoiesis, and multifocal liver tumors. In contrast, mice injected with P815 SHP2 KD cells showed less disease burden, including normal spleen weight and cellularity, and significant reductions in mastocytoma cells in spleen, bone marrow, peripheral blood and liver compared to NT controls. Treatment of human mast cell leukemia HMC-1 cells or P815 cells with SHP2 inhibitor II-B08, resulted in reduced colony formation and cell viability. Combining II-B08 with multi-kinase inhibitor Dasatinib showed enhanced efficacy than either inhibitor alone in blocking cell growth pathways and cell viability. Taken together, these results identify SHP2 as a key effector of oncogenic KIT and a therapeutic target in aggressive SM.

KW - Aggressive systemic mastocytosis

KW - KIT

KW - SHP2 inhibitor

KW - SHP2/PTPN11

UR - http://www.scopus.com/inward/record.url?scp=84906255719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906255719&partnerID=8YFLogxK

M3 - Article

C2 - 25026279

AN - SCOPUS:84906255719

VL - 5

SP - 6130

EP - 6141

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 15

ER -